Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric? (MOCA-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03299855
Recruitment Status : Recruiting
First Posted : October 3, 2017
Last Update Posted : March 29, 2022
Sponsor:
Collaborator:
UCOG (Unite de coordination en Onco-Gériatrie)
Information provided by (Responsible Party):
Centre Francois Baclesse

Brief Summary:

This study concerns elderly patients with cancer with onco-geriatric assessment.

This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.


Condition or disease Intervention/treatment Phase
Neoplasms Other: Passation of neuropsychological test Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Passation of MMS and MoCA tests associated to passation of neuropsychological test
Masking: Single (Participant)
Primary Purpose: Other
Official Title: MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?
Actual Study Start Date : October 13, 2017
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : October 2023

Intervention Details:
  • Other: Passation of neuropsychological test
    Passation of MoCA and MMS tests associated with neuropsychological test


Primary Outcome Measures :
  1. Evaluate the sensitivity of MoCA test [ Time Frame: Up 2 months after inclusion, before initiation of treatment ]
    MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient aged over 70 years
  • Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study.
  • Patient candidate for oncogeriatric assessment
  • Patient agree to participate in the study
  • Using the French language

Exclusion Criteria:

  • Primary central nervous system or cerebral metastasis
  • Evolutionary psychiatric pathology known (e.g. schizophrenia)
  • Severe Visual and / or Auditory Impairment
  • Patients unable to respond to cognitive tests
  • Patient (s) deprived of liberty, under guardianship or curatorship
  • Refusal of participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03299855


Contacts
Layout table for location contacts
Contact: Florence JOLY, PhD 0231455050 f.joly@baclesse.unicancer.fr
Contact: Marie LANGE m.lange@baclesse.unicancer.fr

Locations
Layout table for location information
France
Centre François Baclesse Recruiting
Caen, France
Contact: Florence JOLY, Prof         
CHU Recruiting
Caen, France
Contact: Bérengère BEAUPLET, MD         
CH Recruiting
Cherbourg, France
Contact: Laure KALUZINSKI, MD         
Ch Compiegne Recruiting
Compiègne, France
Contact: Laurence DELTOUR, MD         
Centre Henri Becquerel Not yet recruiting
Rouen, France
Contact: Olivier RIGAL, MD         
Centre Hospitalier Not yet recruiting
Saint-Lô, France
Contact: Isabelle CRINIERE, MD         
Sponsors and Collaborators
Centre Francois Baclesse
UCOG (Unite de coordination en Onco-Gériatrie)
Investigators
Layout table for investigator information
Principal Investigator: florence JOLY, PhD Centre François Baclesse
Layout table for additonal information
Responsible Party: Centre Francois Baclesse
ClinicalTrials.gov Identifier: NCT03299855    
Other Study ID Numbers: 2017-A01079-44
First Posted: October 3, 2017    Key Record Dates
Last Update Posted: March 29, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Francois Baclesse:
oncogeriatric
MMS
MoCA
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognition Disorders
Neurocognitive Disorders
Mental Disorders